Citations

Clear

959 citation(s) found for "Service, F J".

Guidelines for management of actual or suspected inadvertent intra-arterial injection of sclerosants
Parsi, Kurosh , Maeseneer, Marianne De , Rij, André M. van , Bonython, Wendy , Devereux, John , Lekich, C, Amos, Michael, Bozkurt, Ahmet Kursat , Connor, David , Gianesini, Sergio , Gibson, Kathleen , Grabs, Anthony J., Grillo, Lorena, Hafner, Franz, Iafrati, Mark D. , Jackson, Mark , Jindal, Ravul , Raymond-Martimbeau, Pauline, Paraskevas, P, Ramelet, Albert‐Adrien , Roberts, Stefania , Simkin, Carlos, Thibault, P , Whiteley, Mark S , Lim, Adrian , De Maeseneer, Marianne , Bozkurt, Ahmet Kursat , Connor, David E , Davies, Alun H , Gianesini, Sergio , Gibson, Kathleen , Raymond-Martimbeau, Pauline , Thibault, Paul K , Whiteley, Mark S , Parsi, Kurosh , Rogan, Christopher , Davies, Alun H. , Gloviczki, Péter , Huber, David, Lim, Adrian, Lurie, Fedor , Marks, Lisa, Rial, Rodrigo

Mayo Clinic

Phlebology: The Journal of Venous Disease | July 24, 2024 | Volume: 39 | Issue: 10 | Pages: 683-719

10.1177/02683555241260926 | PMID 39046331 Get It

Background Inadvertent intra-arterial injection of sclerosants is an uncommon adverse event of both ultrasound-guided and direct vision sclerotherapy. This complication can result in significant tissue or limb loss and significant long-term morbidity. Objectives To provide recommendations for diagnosis and immediate management of an unintentional intra-arterial injection of sclerosing agents. Methods An international and multidisciplinary expert panel representing the endorsing societies and relevant specialities reviewed the published biomedical, scientific and legal literature and developed the consensus-based recommendations. Results Actual and suspected cases of an intra-arterial sclerosant injection should be immediately transferred to a facility with a vascular/interventional unit. Digital Subtraction Angiography (DSA) is the key investigation to confirm the diagnosis and help select the appropriate intra-arterial therapy for tissue ischaemia. Emergency endovascular intervention will be required to manage the risk of major limb ischaemia. This includes intra-arterial administration of vasodilators to reduce vasospasm, and anticoagulants and thrombolytic agents to mitigate thrombosis. Mechanical thrombectomy, other endovascular interventions and even open surgery may be required. Lumbar sympathetic block may be considered but has a high risk of bleeding. Systemic anti-inflammatory agents, anticoagulants, and platelet inhibitors and modifiers would complement the intra-arterial endovascular procedures. For risk of minor ischaemia, systemic oral anti-inflammatory agents, anticoagulants, vasodilators and antiplatelet treatments are recommended. Conclusion Inadvertent intra-arterial injection is an adverse event of both ultrasound-guided and direct vision sclerotherapy. Medical practitioners performing sclerotherapy must ensure completion of a course of formal training (specialty or subspecialty training, or equivalent recognition) in the management of venous and lymphatic disorders (phlebology), and be personally proficient in the use of duplex ultrasound in vascular (both arterial and venous) applications, to diagnose and provide image guidance to venous procedure. Expertise in diagnosis and immediate management of an intra-arterial injection is essential for all practitioners performing sclerotherapy.
Lymphoma Classifications, How to Develop a Future Unified Taxonomy
Dierickx, Daan , Dirnhofer, Stefan , Dunleavy, Kieron , Hasserjian, Robert P. , Kim, Won Seog, King, Rebecca L. , Ott, German , Siebert, Reiner , Dirnhofer, S , Gaulard, Philippe , Piris, Miguel , Dunleavy, Kieron , Campo, Elı́as , Jaffe, Elaine S. , Kim, Won Seog , Lim, Megan S. , Piris, Miguel Á. , Salles, Gilles

Mayo Clinic

Journal of Clinical Oncology | July 17, 2024 | Volume: 42 | Issue: 27 | Pages: 3177-3182

10.1200/jco.24.00070 | PMID 39018505 Get It

Artificial intelligence in cardiovascular medicine: clinical applications
Lüscher, Thomas F. , Wenzl, Florian A. , D’Ascenzo, Fabrizio , Friedman, Paul A. , Antoniades, Charalambos , Luescher, T F

Mayo Clinic

European Heart Journal | July 17, 2024 | Volume: 45 | Issue: 40 | Pages: 4291-4304

10.1093/eurheartj/ehae465 | PMID 39158472 Get It

Abstract Clinical medicine requires the integration of various forms of patient data including demographics, symptom characteristics, electrocardiogram findings, laboratory values, biomarker levels, and imaging studies. Decision-making on the optimal management should be based on a high probability that the envisaged treatment is appropriate, provides benefit, and bears no or little potential harm. To that end, personalized risk–benefit considerations should guide the management of individual patients to achieve optimal results. These basic clinical tasks have become more and more challenging with the massively growing data now available; artificial intelligence and machine learning (AI/ML) can provide assistance for clinicians by obtaining and comprehensively preparing the history of patients, analysing face and voice and other clinical features, by integrating laboratory results, biomarkers, and imaging. Furthermore, AI/ML can provide a comprehensive risk assessment as a basis of optimal acute and chronic care. The clinical usefulness of AI/ML algorithms should be carefully assessed, validated with confirmation datasets before clinical use, and repeatedly re-evaluated as patient phenotypes change. This review provides an overview of the current data revolution that has changed and will continue to change the face of clinical medicine radically, if properly used, to the benefit of physicians and patients alike.
Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox–Gastaut syndrome in clinical practice
Wirrell, Elaine , Lagae, Lieven , Scheffer, Ingrid E. , Cross, J. Helen , Wirrell, Elaine C , Specchio, Nicola , Strzelczyk, Adam , Cross, Helen J , Scheffer, Ingrid E , Specchio, Nicola

Mayo Clinic

Epilepsia Open | July 4, 2024 | Volume: 9 | Issue: 5 | Pages: 1643-1657

10.1002/epi4.12998 | PMID 38962968 Get It

AbstractFenfluramine (FFA), an antiseizure medication (ASM) with serotonergic and sigma‐1 receptor activity, is used to manage patients with developmental and epileptic encephalopathies (DEEs). It is approved in the US for treating seizures associated with Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS) in patients ≥2 years old and as add‐on therapy for seizures associated with DS and LGS in the EU, UK, and Japan in similarly aged patients. Consensus guidelines for treatment of DS have recommended FFA to be an early‐line ASM, and it has also shown efficacy in managing seizures associated with LGS. DS and LGS are DEEs associated with a range of seizure types, developmental impairments, and multiple comorbidities. Here we provide case vignettes describing 4 patients (3 DS and 1 LGS) aged 4–29 years old in whom up to 14 ASMs had previously failed, to illustrate real‐world practice issues encountered by neurologists. This review provides guidance on the use of FFA in the context of ASM polytherapy and drug–drug interactions (DDIs), behavioral issues, dose titration, and adverse events. Along with data from the clinical trial program, these case vignettes emphasize the low risk of DDIs, a generally well‐tolerated safety profile, and other seizure and nonseizure benefits (eg, improved cognition and sleep) associated with the use of FFA in DS or LGS.Plain Language SummaryFenfluramine is used to treat seizures in individuals with Dravet syndrome and Lennox–Gastaut syndrome, but there are a range of issues that clinicians may face when treating patients. This review highlights four patients from the authors’ everyday clinical work and offers guidance and practical considerations by neurologists with expertise in managing these complex conditions related to drug interactions, dosing, and side effects associated with fenfluramine.
Heart failure with preserved ejection fraction management: a systematic review of clinical practice guidelines and recommendations
Mahmood, Adil , Dhall, Eamon , Gallagher, Angela , Zakeri, Rosita , Mohammed, Selma F. , Ricci, Fabrizio , Aung, Nay , Khanji, Mohammed Y , Gallagher, Angela , Chahal, Anwar A, Ricci, Fabrizio , Aung, Nay , Khanji, Mohammed Yunus , Zakeri, Rosita , Primus, C , Chahal, C. Anwar A. , Ricci, Fabrizio

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | June 26, 2024 | Volume: 10 | Issue: 7 | Pages: 571-589

10.1093/ehjqcco/qcae053 | PMID 38918060 Get It

Abstract Multiple guidelines exist for the diagnosis and management of heart failure with preserved ejection fraction (HFpEF). We systematically reviewed current guidelines and recommendations, developed by national and international medical organizations, on the management of HFpEF in adults to aid clinical decision-making. We searched MEDLINE and EMBASE on 28 February 2024 for publications over the last 10 years as well as websites of organizations relevant to guideline development. Of the 10 guidelines and recommendations retrieved, 7 showed considerable rigour of development and were subsequently retained for analysis. There was consensus on the definition of HFpEF and the diagnostic role of serum natriuretic peptides and resting transthoracic echocardiography. Discrepancies were identified in the thresholds of serum natriuretic peptides and transthoracic echocardiography parameters used to diagnose HFpEF. There was agreement on the general pharmacological and supportive management of acute and chronic HFpEF. However, differences exist in strategies to identify and address specific phenotypes. Contemporary guidelines for HFpEF management agree on measures to avoid its development and the consideration of cardiac transplantation in advanced diseases. There were discrepancies in recommended frequency of surveillance for patients with HFpEF and sparse recommendations on screening for HFpEF in the general population, use of diagnostic scoring systems, and the role of newly emerging therapies.
Brugada syndrome: can polygenic risk scores help the clinician?
Behr, Elijah R. , Behr, Elijah Raphael

Mayo Clinic

European Heart Journal | June 11, 2024 | Volume: 45 | Issue: 26 | Pages: 2333-2335

10.1093/eurheartj/ehae364 | PMID 38860730 Get It

Severe Pediatric Neurological Manifestations With SARS-CoV-2 or MIS-C Hospitalization and New Morbidity
Francoeur, Conall , Robertson, Courtney , Wainwright, Mark S. , Roa, Juan D. , Lovett, Marlina E. , Stulce, Casey , Yacoub, M, Potera, Renee M. , Zivick, Elizabeth, Holloway, Adrian , Nagpal, Ashish, Even, Katelyn , Rodriguez, Isadora Souza , Walker, Tracie C. , Campos-Miño, Santiago , Sewell, Taylor B. , Pryce, Patrice , Silver, Wendy G. , Lin, Jieru E. , Vargas, Wendy , McGuire, Jennifer L. , Tasayco-Muñoz, Jaime , Hong, Sue J. , Doerfler, Matthew , Williams, Cydni N. , Drury, Kurt , Bhagat, Dhristie, Price, Dana C. , Santos, Laura Jurema dos , Kahoud, Robert J., Agner, Shannon C. , Walson, Karen, Rasmussen, Lindsey , Pal, Ria , Janas, Anna , Ferrazzano, Peter , Farias‐Moeller, Raquel , Snooks, Kellie , Chang, Chung‐Chou H. , Iolster, Tomás, Erklauer, Jennifer , Yoong, Michael , Jardine, Michelle, Mohammad, Zoha, Deep, Akash , Kendirli, Tanıl , Lidsky, Karen , Dallefeld, Samantha , Flockton, Helen, Agrawal, Shruti , Siruguppa, K., Gutiérrez-Mata, Alfonso, Bogantes-Ledezma, Sixto , Sevilla-Acosta, Fabricio , Umaña-Calderón, Andrés , Ulate-Campos, Adriana , Talisa, Victor B. , Kanthimathinathan, Hari Krishnan , Schober, Michelle E. , Kahoud, Robert, Wainwright, Mark S , Alcamo, Alicia M. , Yacoub, Mais, Wellnitz, Kari , Carvalho, Werther Brunow de , Schwartz, Stephanie P. , Dervan, Leslie A. , Geneslaw, Andrew S. , Topjian, Alexis , Domínguez-Rojas, Jesús , Muller, William J. , Nelson, Aaron L.A. , Price, Dana, Dapul, Heda , Appavu, Brian , Guilliams, Kristin P. , Barón, Facundo Jorro , Wassmer, Evangeline , Waak, Michaela , Butt, Warwick W. , Yock‐Corrales, Adriana , Fink, Ericka L.

Mayo Clinic

JAMA Network Open | June 10, 2024 | Volume: 7 | Issue: 6 | Pages: e2414122

10.1001/jamanetworkopen.2024.14122 | PMID 38857050 Get It

Importance Neurological manifestations during acute SARS-CoV-2–related multisystem inflammatory syndrome in children (MIS-C) are common in hospitalized patients younger than 18 years and may increase risk of new neurocognitive or functional morbidity. Objective To assess the association of severe neurological manifestations during a SARS-CoV-2–related hospital admission with new neurocognitive or functional morbidities at discharge. Design, Setting, and Participants This prospective cohort study from 46 centers in 10 countries included patients younger than 18 years who were hospitalized for acute SARS-CoV-2 or MIS-C between January 2, 2020, and July 31, 2021. Exposure Severe neurological manifestations, which included acute encephalopathy, seizures or status epilepticus, meningitis or encephalitis, sympathetic storming or dysautonomia, cardiac arrest, coma, delirium, and stroke. Main Outcomes and Measures The primary outcome was new neurocognitive (based on the Pediatric Cerebral Performance Category scale) and/or functional (based on the Functional Status Scale) morbidity at hospital discharge. Multivariable logistic regression analyses were performed to examine the association of severe neurological manifestations with new morbidity in each SARS-CoV-2–related condition. Results Overall, 3568 patients younger than 18 years (median age, 8 years [IQR, 1-14 years]; 54.3% male) were included in this study. Most (2980 [83.5%]) had acute SARS-CoV-2; the remainder (588 [16.5%]) had MIS-C. Among the patients with acute SARS-CoV-2, 536 (18.0%) had a severe neurological manifestation during hospitalization, as did 146 patients with MIS-C (24.8%). Among survivors with acute SARS-CoV-2, those with severe neurological manifestations were more likely to have new neurocognitive or functional morbidity at hospital discharge compared with those without severe neurological manifestations (27.7% [n = 142] vs 14.6% [n = 356]; P < .001). For survivors with MIS-C, 28.0% (n = 39) with severe neurological manifestations had new neurocognitive and/or functional morbidity at hospital discharge compared with 15.5% (n = 68) of those without severe neurological manifestations ( P = .002). When adjusting for risk factors in those with severe neurological manifestations, both patients with acute SARS-CoV-2 (odds ratio, 1.85 [95% CI, 1.27-2.70]; P = .001) and those with MIS-C (odds ratio, 2.18 [95% CI, 1.22-3.89]; P = .009) had higher odds of having new neurocognitive and/or functional morbidity at hospital discharge. Conclusions and Relevance The results of this study suggest that children and adolescents with acute SARS-CoV-2 or MIS-C and severe neurological manifestations may be at high risk for long-term impairment and may benefit from screening and early intervention to assist recovery.
Development of a Consensus-Derived Synoptic Operative Report for Rectal Prolapse: A Report From the Pelvic Floor Disorders Consortium
Olson, Craig , Bordeianou, Lilliana, Perry, William , Mellgren, Anders, Wells, Katerina , Oliveira, Lúcia , Gurland, Brooke , Olson, Craig H , Perry, William R , Ferrari, Linda , Spivak, Anna R., Ratto, Carlo

Mayo Clinic

Diseases of the Colon & Rectum | June 3, 2024 | Volume: 67 | Issue: 9 | Pages: 1169-1176

10.1097/dcr.0000000000003364 | PMID 38830262 Get It

BACKGROUND: Narrative operative reports may omit or obscure data from an operation. OBJECTIVE: To develop a synoptic operative report for rectal prolapse that includes core descriptors as developed by an international consensus of expert pelvic floor surgeons. DESIGN: Descriptors for patients undergoing rectal prolapse surgery were generated through review. Members of the Pelvic Floor Disorders Consortium were recruited to participate in a 3-round Delphi process using a 9-point Likert scale. Descriptors that achieved 70% agreement were kept from the first round, and descriptors scoring 40% to 70% agreement were recirculated in subsequent rounds. A final list of operative descriptors was determined at a consensus meeting, with a final consensus meeting more than 70% agreement. SETTINGS: This survey was administered to members of the Pelvic Floor Disorders Consortium. PATIENTS: No patient data are included in this study. MAIN OUTCOME MEASURES: Descriptors meeting greater than 70% agreement were selected. RESULTS: One hundred seventy-six surgeons representing colorectal surgeons, urogynecologists, and urologists distributed throughout North America (56%), Latin America (4%), Western Europe (29%), Asia (4%), and Africa (1%) participated in the first round of Delphi voting. After 2 additional rounds and a final consensus meeting, 16 of 30 descriptors met 70% consensus. Descriptors that met consensus were surgery type, posterior dissection, ventral dissection, mesh used, type of mesh used, mesh location, sutures used, suture type, pouch of Douglas and peritoneum reclosed, length of rectum imbricated, length of bowel resected, levatoroplasty, simultaneous vaginal procedure, simultaneous gynecologic procedure, simultaneous enterocele repair, and simultaneous urinary incontinence procedure. LIMITATIONS: The survey represents the views of members of the Delphi panel and may not represent the viewpoints of all surgeons. CONCLUSIONS: This Delphi survey establishes international consensus descriptors for intraoperative variables that have been used to produce a synoptic operative report. This will help establish defined operative reporting to improve clinical communication, quality measures, and clinical research. See Video Abstract. DESARROLLO DE UN PROTOCOLO OPERATORIO SINÓPTICO DERIVADO DE CONSENSO PARA EL PROLAPSO RECTAL: UN INFORME DEL CONSORCIO DE TRASTORNOS DEL PISO PÉLVICO ANTECEDENTES: Los protocolos operativos narrativos frecuentemente pueden omitir u oscurecer datos de un procedimiento. OBJETIVO: Nuestro objetivo es desarrollar un protocolo operatorio sinóptico para el prolapso rectal que incluya descriptores básicos desarrollados por un consenso internacional de cirujanos expertos en piso pélvico. DISEÑO: Los descriptores para pacientes sometidos a cirugía de prolapso rectal se generaron mediante revisión. Se reclutó a miembros del Consorcio de Trastornos del Piso Pélvico para participar en un proceso Delphi de 3 rondas utilizando una escala Likert de 9 puntos. Los descriptores que lograron un 70% de acuerdo se mantuvieron en la primera ronda, los descriptores que obtuvieron un 40-70% de acuerdo se recircularon en rondas posteriores. Se determinó una lista final de descriptores operativos en una reunión de consenso, con una reunión de consenso final de más del 70% de acuerdo. ESCENARIO: Esta fue una encuesta administrada a miembros del Consorcio de Trastornos del Piso Pélvico. PRINCIPALES MEDIDAS DE RESULTADO: Se seleccionaron los descriptores que cumplieron más del 70% de acuerdo. RESULTADOS: Ciento setenta y seis cirujanos en representación de cirujanos colorrectales, uroginecólogos y urólogos distribuidos en América del Norte (56%), América Latina (4%), Europa Occidental (29%), Asia (4%) y África (1%) participaron en la primera ronda de votación Delphi. Después de dos rondas adicionales y una reunión de consenso final, 16 de 30 descriptores alcanzaron un 70% de consenso. Los descriptores que alcanzaron consenso fueron: tipo de cirugía, disección posterior, disección ventral, malla utilizada, tipo de malla utilizada, ubicación de la malla, suturas utilizadas, tipo de sutura, cierre del fondo de saco de Douglas y peritoneo, longitud del recto superpuesto, longitud del intestino resecado, plastía de los elevadores , procedimiento vaginal simultáneo, procedimiento ginecológico simultáneo, reparación simultánea de enterocele y procedimiento simultáneo de incontinencia urinaria. LIMITACIONES: La encuesta representa las opiniones de los miembros del panel Delphi y puede no representar los puntos de vista de todos los cirujanos. CONCLUSIONES/DISCUSIÓN: Esta encuesta Delphi establece descriptores de consenso internacional para las variables intraoperatorias que se han utilizado para producir un protocolo operatorio sinóptico. Esto ayudará a establecer protocolos operativos definidos para mejorar la comunicación clínica, las medidas de calidad y la investigación clínica. (Traducción—Dr. Felipe Bellolio)
Spirulina (Arthrospira platensis) Improved Nonalcoholic Fatty Liver Disease Characteristics and Microbiota and Did Not Affect Organ Fibrosis Induced by a Fructose-Enriched Diet in Wistar Male Rats
Fakhoury-Sayegh, Nicole , Hamdan, Aya , Lebbos, Sarah, Trak-Smayra, Viviane , Khazzaka, Aline , Dagher‐Hamalian, Carole , Sayegh, Lea N. , Mallah, May , Obeid, Omar , Sayegh, Raymond, Khazzaka, Aline , Sayegh, Lea Nicole , Itani, Tarek M.

Mayo Clinic

Nutrients | May 30, 2024 | Volume: 16 | Issue: 11 | Pages: 1701

10.3390/nu16111701 | PMID 38892633 Get It

Spirulina (Arthrospira platensis) is reported to play a role in improving nonalcoholic fatty liver disease (NAFLD) and intestinal microbiota (IM). To study spirulina’s effects in the improvement of NAFLD characteristics, IM, and pancreatic–renal lesions induced by a fructose-enriched diet, 40 Wistar healthy male rats, weighing 200–250 g, were randomly divided into four groups of 10, and each rat per group was assigned a diet of equal quantities (20 g/day) for 18 weeks. The first control group (CT) was fed a standardized diet, the second group received a 40% fructose-enriched diet (HFr), and the third (HFr-S5) and fourth groups (HFr-S10) were assigned the same diet composition as the second group but enriched with 5% and 10% spirulina, respectively. At week 18, the HFr-S10 group maintained its level of serum triglycerides and had the lowest liver fat between the groups. At the phylae and family level, and for the same period, the HFr-S10 group had the lowest increase in the Firmicutes/Bacteroidetes ratio and the Ruminococcaceae and the highest fecal alpha diversity compared to all other groups (p < 0.05). These findings suggest that at a 10% concentration, spirulina could be used in nutritional intervention to improve IM, fatty liver, metabolic, and inflammatory parameters associated with NAFLD.